InMed Pharmaceuticals (FRA:MWG) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


FRA:MWG InMed Pharmaceuticals Inc FRA:MWG
29 GF Score
Price €1.27
GF Value €0.76
! 3 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

InMed Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:MWG vs GELS, LVRLF, BUDZ: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InMed Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


FRA:MWG
29GF Score
InMed Pharmaceuticals Inc FRA:MWG
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InMed Pharmaceuticals (FRA:MWG) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of €1.27 is trading 67.1% above its estimated GF Value™ of €0.76.

Key valuation signals for FRA:MWG:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.76 vs. price of €1.27 (67.1% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the FRA:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InMed Pharmaceuticals Business Description

Other Exchanges INM:USA
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score

Get the complete analysis for FRA:MWG

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.27
Price
€0.76
GF Value